547 related articles for article (PubMed ID: 29307995)
1. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT; Fuchs M; Ridlon JM; Daita K; Monteith P; Noble NA; White MB; Fisher A; Sikaroodi M; Rangwala H; Gillevet PM
PLoS One; 2013; 8(4):e60042. PubMed ID: 23565181
[TBL] [Abstract][Full Text] [Related]
3. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
4. Linkage of gut microbiome with cognition in hepatic encephalopathy.
Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.
Ahluwalia V; Wade JB; Heuman DM; Hammeke TA; Sanyal AJ; Sterling RK; Stravitz RT; Luketic V; Siddiqui MS; Puri P; Fuchs M; Lennon MJ; Kraft KA; Gilles H; White MB; Noble NA; Bajaj JS
Metab Brain Dis; 2014 Dec; 29(4):1017-25. PubMed ID: 24590688
[TBL] [Abstract][Full Text] [Related]
6. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.
Kaji K; Saikawa S; Takaya H; Fujinaga Y; Furukawa M; Kitagawa K; Ozutsumi T; Kaya D; Tsuji Y; Sawada Y; Kawaratani H; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Antibiotics (Basel); 2020 Mar; 9(4):. PubMed ID: 32235367
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia.
Kalambokis GN; Mouzaki A; Rodi M; Tsianos EV
Liver Int; 2012 Mar; 32(3):467-75. PubMed ID: 22098272
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
12. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.
Kulkarni AV; Avadhanam M; Karandikar P; Rakam K; Gupta A; Simhadri V; Premkumar M; Zuberi AA; Gujjarlapudi D; Narendran R; Shaik S; Sharma M; Iyengar S; Alla M; Venishetty S; Reddy DN; Rao PN
Am J Gastroenterol; 2024 May; 119(5):864-874. PubMed ID: 37942950
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
Pedretti G; Calzetti C; Missale G; Fiaccadori F
Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
[TBL] [Abstract][Full Text] [Related]
14. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
15. Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study.
Zeng X; Tang XJ; Sheng X; Ni W; Xin HG; Chen WZ; Jiang CF; Lin Y; Shi J; Shi B; Chen YX; Yuan ZL; Xie WF
J Dig Dis; 2015 Nov; 16(11):665-74. PubMed ID: 26474237
[TBL] [Abstract][Full Text] [Related]
16. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
[TBL] [Abstract][Full Text] [Related]
17. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy.
Jain L; Sharma BC; Sharma P; Srivastava S; Agrawal A; Sarin SK
Dig Liver Dis; 2012 Dec; 44(12):1027-31. PubMed ID: 22883217
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin in the treatment of chronic hepatic encephalopathy.
Puxeddu A; Quartini M; Massimetti A; Ferrieri A
Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
